股票简称:诺 唯 赞 股票代码: 688105 诺萨萨 "提质增效重回报" 专项行动方案 2024 半年度评估报告 南京诺唯赞生物科技股份有限公司 Nanjing Vazyme Biotech Co.,Ltd. 为积极践行"以投资者为本"的上市公司发展理念,维护公司全体股东利益,基于对公司未来 发展信心及价值认可,南京诺唯赞生物科技股份有限公司(以下简称"公司")制定并于 2024 年 4 月 27 日披露了《2024 年度"提质增效重回报"行动方案》( 以下简称"行动方案")。 2024 年上半年,行动方案主要举措的落实进展及成效如下: 聚焦主业 打造科技创新实力 1、专注主业,持续稳步发展 报告期内,公司生命科学板块新产品线业务、国际业务增长快速,整体销售收入规模稳步增长。通过持续 推进日常经营管理的降本增效,公司整体费用率同比显著改善。同时,公司通过多项举措加强采购、生 产、存货等多环节管理,有效降低了库存减值风险,资产减值损失计提金额同比大幅下降。 生物科技领域的核心原料 诺唯赞提供场景化、行业级解决方案 · 重大急、慢性疾病诊断试剂和检测设备 坚持以酶和蛋白质技术创新作为核心竞争力,坚持打造: · ...

证券代码：688105 证券简称：诺唯赞 公告编号：2024-047 南京诺唯赞生物科技股份有限公司 2024年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第2号—上市公司募集资 金管理和使用的监管要求（2022年修订）》（证监会公告〔2022〕15号）《上海 证券交易所科创板上市公司自律监管指引第1号—规范运作（2023年12月修订）》 以及《上海证券交易所上市公司自律监管指南第1号—公告格式（2024年5月修订） 》的相关规定，南京诺唯赞生物科技股份有限公司（以下简称"公司"）就2024 年半年度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意南京诺唯赞生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]2367号文）核准，公司向社会公 开发行人民币普通股（A股）40,010,000股，每股面值人民币1.00元。截至202 ...

Financial Performance - The company reported a half-year revenue of RMB 1.2 billion, representing a year-on-year increase of 25%[1]. - Nanjing Vazyme Biotech Co., Ltd. reported a significant increase in revenue, achieving a total of 500 million RMB in the first half of 2024, representing a 25% year-over-year growth[14]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2024, representing a year-over-year growth of 25%[87]. - The company's operating revenue for the first half of 2024 reached ¥649,272,421, representing a year-on-year increase of 13.70% compared to ¥571,036,914 in the same period last year[19]. - The net profit attributable to shareholders was ¥16,159,452.81, a significant turnaround from a loss of ¥81,093,535.29 in the previous year[19]. - The net profit attributable to shareholders was 16.16 million RMB, an increase of 9.73 million RMB compared to the same period last year[181]. - The company has set a revenue guidance of 1 billion RMB for the full year 2024, indicating a projected growth of 20% compared to 2023[14]. User Growth - User data indicates a growth in active users by 15%, reaching a total of 500,000 users[1]. - User data indicates that the customer base has grown by 30%, reaching over 1 million active users in the first half of 2024[14]. - User data showed an increase in active users by 15%, reaching a total of 2 million active users as of June 2024[87]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[1]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 10% market share by the end of 2025[14]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[87]. Research and Development - Research and development expenses increased by 20%, totaling RMB 150 million, focusing on new biotechnologies[1]. - Nanjing Vazyme is investing in R&D, allocating 15% of its revenue to develop new technologies and improve existing products[14]. - The company's R&D expenditure as a percentage of operating revenue decreased by 8.15 percentage points to 21.95%[20]. - R&D expenses totaled ¥142,484,756.24, a decrease of 17.11% compared to ¥171,886,906.66 in the same period last year[93]. - R&D expenses accounted for 21.95% of total revenue, down 8.15 percentage points from 30.10% in the previous year[93]. - The company has completed 36 technical studies and developed 22 products in the NGS-related products and technology development project, with a total investment of ¥12,000.00 million[95]. Product Development - New product launches include three innovative diagnostic kits, expected to contribute an additional RMB 200 million in revenue[1]. - The company has expanded its product portfolio, launching 10 new products in the first half of 2024, which contributed to 15% of total sales[14]. - New product development includes the launch of five new diagnostic kits, which are expected to contribute an additional 200 million RMB in revenue by the end of 2024[87]. - The company has developed over 600 types of recombinant enzymes and more than 2,500 types of high-performance antigens and monoclonal antibodies, forming over 2,000 end products[25]. - The company has launched a series of in vitro diagnostic products, including POCT diagnostic reagents for rare indicators such as anti-PLA2R and NFL, enhancing early disease detection capabilities[36]. Financial Management - The company has no plans for mergers or acquisitions in the upcoming year, focusing instead on organic growth strategies[1]. - The company has identified potential risks related to regulatory changes that could impact future operations[1]. - The company has reported a significant reduction in borrowing, contributing to the stability of net assets[21]. - The company has achieved significant advancements in quantum dot technology, enabling multi-indicator testing from a single sample, improving efficiency and convenience[36]. Strategic Partnerships - Nanjing Vazyme has established strategic partnerships with three major pharmaceutical companies to enhance its distribution network[14]. - The company has established partnerships with 9 institutions for the development of key raw materials for in vitro diagnostic reagents, which is part of a national key research and development plan[172]. Risk Management - The company has identified potential risks related to regulatory changes that could impact future operations[1]. - The company faces risks related to product development and technology iteration, including potential failures due to high costs or slow progress in R&D[174]. - The company acknowledges the risk of market competition intensifying, with many domestic and international firms entering the biotechnology and in vitro diagnostics markets[175]. Operational Efficiency - The company reported a gross margin of 60% in the first half of 2024, reflecting improved operational efficiency[14]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost control measures and increased sales of high-margin products[87]. - The company has implemented new strategies to enhance customer engagement, resulting in a 20% increase in customer retention rates[14]. International Business - The company has established subsidiaries in regions including Hong Kong, the USA, Canada, Indonesia, Singapore, Germany, the UK, and Australia, enhancing its global delivery capabilities[154]. - The company's international business sales in North America, Europe, and Southeast Asia experienced exponential growth compared to the same period last year, driven by new and repeat customers[153]. Quality Control - The company has established a comprehensive quality management system for its in vitro diagnostic reagents, complying with ISO13485 and various international regulations, successfully passing multiple audits and certifications[165]. - The company has actively engaged in internal quality management audits and continuous improvement initiatives, fostering a culture of quality and efficiency[165].

证券简称：诺唯赞 证券代码：688105 南京诺唯赞生物科技股份有限公司 投资者关系活动记录表 编号：2024-8-1 | --- | --- | --- | |---------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Insights - The company is undergoing a strategic transformation, focusing on downstream products, with significant growth potential driven by Alzheimer's blood tests [2][3]. - The company has entered a fundamental turning point, with expected revenue growth of over 25% in the coming years, supported by overseas market expansion and the launch of key products [4][6]. - The Alzheimer's blood test market is projected to reach 16 billion yuan in China, with the company holding a significant competitive advantage due to its early market entry and strong protein research capabilities [4][5]. Financial Forecast and Valuation - Revenue projections for 2024-2026 are 16.11 billion, 20.62 billion, and 26.44 billion yuan, with year-on-year growth rates of 25%, 28%, and 28% respectively [4][21]. - Net profit forecasts for the same period are 560 million, 2.40 billion, and 4.30 billion yuan, with year-on-year growth rates of 179%, 326%, and 79% respectively [4][21]. - The company is expected to achieve a compound annual growth rate (CAGR) of approximately 81% in net profit over the next three years, with a corresponding price-to-earnings (P/E) ratio of 61, 30, and 19 [4][21]. Business Overview - The company has established itself as a leading provider of life science solutions, focusing on protein development and production capabilities [11][12]. - The strategic shift towards high-volume, high-demand product lines, including respiratory and Alzheimer's detection tests, is expected to enhance market share and revenue [11][12]. - The company has successfully commercialized six Alzheimer's blood test products, covering various clinical applications [14][28]. Market Dynamics - The report highlights the increasing demand for Alzheimer's testing due to rising prevalence rates, with the global number of dementia patients projected to reach 139 million by 2050 [28]. - The company is well-positioned to capitalize on the growing market for early detection and monitoring of Alzheimer's disease, leveraging its technological advantages and established market presence [4][28].

证券代码：688105 证券简称：诺唯赞 公告编号：2024-044 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/6，由公司董事长兼总经理、实际控制人 | | | --- | --- | --- | | | 曹林先生提议 | | | 回购方案实施期限 | 公司董事会审议通过后 12 个月 | | | 预计回购金额 | 8,000 万元 | 万元~16,000 | | 回购用途 | □用于员工持股计划或股权激励 | √减少注册资本 | | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 4,161,077 | 股 | | 累计已回购股数占总股本比例 | 1.04% | | | 累计已回购金额 | 10,144.57 | 万元 | | 实际回购价格区间 | 18.80 元/股 | 元/股~28.65 | 一、 回购股份的基本情况 南京诺唯赞 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2024-043 南京诺唯赞生物科技股份有限公司 关于自愿披露子公司产品取得 欧盟CE IVDR认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）全资子公司南京诺 唯赞医疗科技有限公司部分产品于近日取得欧盟 CE IVDR 认证，可在欧盟国家和 认可欧盟 CE 认证的国家进行销售，具体情况如下： 二、对公司的影响及风险提示 本次公司产品欧盟 CE IVDR 准入资质的取得，是公司微流控技术平台商业化 进程与国际化战略推进的重要里程碑，继公司体外诊断化学发光平台产品上市后， 进一步丰富了公司体外诊断业务方法学平台与产品类型，有利于增强公司体外诊 断业务的市场竞争力，更好地探索国际市场。 （一）认证信息 | 序 | 名称 | 分类 | | 有效期 | 预期用途 | 参考图示 | | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | | | | | 1 | Lo ...

Revenue and Profit Projections - The company expects to achieve operating revenue between 640 million and 660 million CNY for the first half of 2024, an increase of 68.96 million to 88.96 million CNY, representing a year-on-year growth of 12.08% to 15.58%[2]. - The net profit attributable to the parent company is projected to be between 15 million and 17 million CNY, marking a turnaround from a loss in the same period last year[2]. - After excluding share-based payment expenses of approximately 38 million CNY, the adjusted net profit is expected to be between 47.35 million and 49.35 million CNY, an increase of 124.71 million to 126.71 million CNY year-on-year[2]. - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is expected to be between -15.5 million and -13.5 million CNY, reflecting a significant narrowing of losses compared to the previous year[2]. - In the same period last year, the company reported an operating revenue of 571.04 million CNY and a net loss of 81.09 million CNY[11]. Business Growth and Management Initiatives - The company has seen rapid growth in its life sciences segment and international business, contributing to steady revenue growth[12]. - The overall expense ratio has significantly improved year-on-year due to ongoing cost reduction and efficiency enhancement measures[12]. - The company has implemented multiple initiatives to strengthen management across procurement, production, and inventory, effectively reducing inventory impairment risks[12]. Forecast Accuracy and Financial Data - The company has not identified any significant uncertainties that could affect the accuracy of this earnings forecast[7]. - The financial data in this earnings forecast has not been audited by a registered accountant and is based on preliminary internal calculations[3].

华泰联合证券有限责任公司 关于南京诺唯赞生物科技股份有限公司 差异化分红事项的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作为南京诺 唯赞生物科技股份有限公司（以下简称"诺唯赞"、"公司"或"发行人"）首次公开发行 股票的保荐人，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）及《上海证券交易所上市公司自 律监管指引第 7 号——回购股份》等有关规定，对诺唯赞 2023 年度利润分配所涉及的 差异化分红事项进行了核查，核查情况如下： 一、本次差异化分红的原因 2023 年 8 月 21 日，公司第二届董事会第三次会议审议通过了《关于以集中竞价 交易方式回购公司股份方案的议案》，同意公司使用自有资金通过集中竞价交易方式 进行股份回购。回购股份将全部用于员工持股计划或股权激励，回购价格不超过 45.00 元/股（含），回购资金总额不低于人民币 2,000 万元（含），不超过人民币 3,000 万 元（含）。 截至 2023 年 11 月 24 日，公司已完成本次回购，实际回购公司股份 618,077 股， 全部回购股份目前存 ...

重要内容提示： | 回购方案首次披露日 | 2024/2/6，由公司董事长兼总经理、实际控制人 | | | --- | --- | --- | | | 曹林先生提议 | | | 回购方案实施期限 | 公司董事会审议通过后 12 个月 | | | 预计回购金额 | 8,000 万元 | 万元~16,000 | | 回购用途 | | √减少注册资本 | | | □用于员工持股计划或股权激励 | | | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 4,086,577 | 股 | | 累计已回购股数占总股本比例 | 1.02% | | | 累计已回购金额 | 10,000.99 | 万元 | | 实际回购价格区间 | 22.63 元/股 | 元/股~28.65 | 证券代码：688105 证券简称：诺唯赞 公告编号：2024-039 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至 2024 年 ...